Építés alatt – nem éles oldal
Belépés
Résztvevőt keresFázis nélkül

Halo Sign Vanishing Time After Steroids Outbreak in GCA Patients

A legfontosabb adatok

Ki végzi
Centre Hospitalier le Mans
Hol
Franciaország6 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Résztvevők
64 fő, tervezett
Kezdés
2026. febr. 27.
Várható befejezés
2028. febr.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Doppler Ultrasound
A regiszteradat frissítve
2026. július 17.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for people aged 50 and over with newly diagnosed giant cell arteritis (GCA). They must show a halo sign on Doppler ultrasound of the temporal artery and be about to start corticosteroid treatment.

Életkor
50 years and over
Nem
All sexes
A betegség stádiuma
Newly diagnosed GCA meeting the ACR 2022 classification criteria. A halo sign on one or both sides on Doppler ultrasound of the temporal artery. Corticosteroid treatment is needed.
Korábbi kezelés
No corticosteroid treatment for GCA yet. No oral corticosteroids in the past month and none now (hydrocortisone or local corticosteroids are allowed). No immunosuppressive treatment or biotherapy in the month before joining.
Biomarker vagy leletérték
No ANCA (antibodies against neutrophil cytoplasm), negative syphilis blood test and negative IGRA test.

A részvétel fő kizáró okai

  • GCA that has come back (relapse)
  • A past temporal artery biopsy, for any reason
  • Another type of vasculitis that could explain the symptoms
  • Cannot have corticosteroid treatment
  • Under legal protection or not covered by social security

A regiszter feltételei, szó szerint

Mind a 13 feltétel megnézéseKevesebb

Ki vehet részt

  • Patients aged 50 and over
  • Without legal protection
  • Meeting GCA classification criteria as defined by ACR 2022 with the presence of a halo sign-unilateral or bilateral-on Doppler ultrasound of the temporal artery
  • Newly diagnosed with an indication for corticosteroid treatment
  • Have not yet received corticosteroid treatment for GCA
  • No contraindication to corticosteroid treatment
  • Person affiliated with or benefiting from a social security scheme
  • Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination necessary for the research)

Ki nem vehet részt

  • Patients who have previously undergone a temporal artery biopsy (TAB), including for other reasons
  • Patients who have received oral corticosteroid treatment in the past month or are currently on corticosteroid therapy (excluding hydrocortisone or local corticosteroids)
  • Patients having received immunosuppressive treatment or biotherapy in the month prior to inclusion. If the patient's condition warrants the use of biotherapy or immunosuppressive treatment, its initiation will be delayed until after Day 7 to avoid interfering with the Doppler procedure
  • Patients with other types of vasculitis that may constitute a differential diagnosis: presence of antibodies against the cytoplasm of neutrophils (ANCA), positive syphilis serology, positivity of an IGRA test (Interferon Gamma Release Assay)
  • Patients with a relapse of Giant Cell Arteritis (GCA)

Ez a vizsgálat jelenleg itt érhető el: Franciaország.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Giant cell arteritis (GCA) is a rare disease characterized by vasculitis of the large arterial trunks targeting the thoracic aorta and its dividing branches, affecting adults over the age of 50. Vasculitis lesions cause thickening of the arterial wall, visible on temporal artery biopsy (TAB) or vascular imaging (echo-Doppler, angio-CT, angio-MRI, 18FDG PET-CT). This is a severe disease that can lead to blindness. Early diagnosis is essential, so that steroids therapy can be started as soon as possible to prevent complications. Doppler ultrasonography of the temporal arteries provides rapid, non-invasive diagnostic support. However, the recommendations do not specify how soon temporal artery Doppler should be performed after steroids treatment, except that the halo sign would disappear after about 5 days on steroids. Sensitivity seems to be better when the examination is performed early, but the time taken for the halo sign to disappear is unknown. The investigator suggests that the disappearance of the temporal artery halo sign in GCA patients is observed earlier than D14 of steroids treatment usually reported in the literature. He speculates that the sensitivity of the temporal artery Doppler decreases as early as D3 of steroids treatment, and that beyond D7 it is not useful to perform this examination as its sensitivity becomes too low.

A vizsgálat csoportja

  • Timeframe for Halo sign resolution on Doppler ultrasoundA vizsgált kezelés

    Doppler ultrasound of temporal arteries at D0, D3 and D7 (+/- D15) after initiation of corticosteroid therapy.

    Kezelés: Doppler Ultrasound

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
A regiszteradat frissítve
2026. július 17.